[Analysis of Efficacy and Safety of Neoadjuvant Immunochemotherapy in Patients with Stage IB-IIIB Non-small Cell Lung Cancer].
Neoadjuvant immunochemotherapy is safe and effective for patients with stage IB-IIIB NSCLC. Patients achieving pCR or MPR exhibit significantly better survival benefits from neoadjuvant immunochemotherapy. Squamous cell carcinoma and radiographic objective response can serve as clinical predictors of pathological response.
Authors
- Zhe Cui (ORCID: https://orcid.org/0000-0002-3345-5197)
- Guanchao Jiang
- X Wang
- Xin Wang (ORCID: https://orcid.org/0000-0001-9325-3194)
- Xin Wang (ORCID: https://orcid.org/0000-0002-5489-7963)
- Zihao Li (ORCID: https://orcid.org/0000-0002-4040-8188)
- Xiao Li (ORCID: https://orcid.org/0000-0002-9358-1136)
- Yulong Wang (ORCID: https://orcid.org/0000-0002-0895-6010)
Institutions
- Tianjin Chest Hospital (CN)
Publication Details
- Journal
- PubMed
- Published
- 2025-06-20
- DOI
- https://doi.org/10.3779/j.issn.1009-3419.2025.106.16
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article